Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients

Diabetes Research and Clinical Practice

Volumn 96, Issue 3, 2012, Pages

  Bisgin, A ^a   Yalcin, A D ^b   Gorczynski, R M ^c  

^a AKDENIZ UNIVERSITY   (Turkey)

^b Antalya Education and Research Hospital   (Turkey)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Non drug using diabetic patients; Soluble TRAIL; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; SOLUBLE TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; APOPTOSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84862195187     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.02.028     Document Type: Article

References (19)

1. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
2. Vaccarezza M., Delbello G., Zauli G. A role of the TRAIL-TRAIL receptor system in the pathogenesis of diabetes. Acta Biomed 2007, 78(Suppl. 1):262-267.
3. Hotamisligil G.S. Mechanisms of TNF-alpha-induced insülin resistance. Exp Clin Endocrinol Diabetes 1999, 107:119-125.
4. Rabinovitch A., Suarez-Pinzon W.L. Cytokines and their roles in pancreatic islet beta-cell destruction and insülin-dependent diabetes mellitus. Biochem Pharmacol 1998, 55:1139-1149.
5. Griffith T.S., Lynch D.H. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998, 10(5):559-563.
6. Terzioglu E., Bisgin A., Sanlioglu A.D., Ulker M., Yazisiz V., Tuzuner S., et al. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford) 2007, 46(5):783-789.
7. Sanlioglu A.D., Koksal I.T., Karacay B., Baykara M., Luleci G., Sanlioglu S. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther 2006, 13(1):21-31.
8. Aydin C., Sanlioglu A.D., Bisgin A., Yoldas B., Dertsiz L., Karacay B., et al. NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL. BMC Cancer 2010, 10(October):584.
9. Kawano N., Mori K., Emoto M., Lee E., Kobayashi I., Yamazaki Y., et al. Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011, 91(March (3)):316-320. [epub 2011 Jan 11].
10. Ziegler S., Kudlacek S., Luger A., Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005, 182:175-180.
11. Michowitz Y., Goldstein E., Roth A., Afek A., Abashidze A., Ben Gal Y., et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005, 45:1018-1024.
12. Deftereos S., Giannopoulos G., Kossyvakis C., Kaoukis A., Raisakis K., Panagopoulou V., et al. Association of soluble tumour necrosis factor-related apoptosis-inducing ligand levels with coronary plaque burden and composition. Heart 2012, 98(February (3)):214-218. [epub 2011 Oct 1].
13. Salehi E., Vodjgani M., Massoud A., Keyhani A., Rajab A., Shafaghi B., et al. Increased expression of TRAIL and its receptors on peripheral T-cells in type 1 diabetic patients. Iran J Immunol 2007, 4(December (4)):197-205.
14. Dirice E., Kahraman S., Elpek G.O., Aydin C., Balci M.K., Omer A., et al. TRAIL and DcR1 expressions are differentially regulated in the pancreatic islets of STZ- versus CY-applied NOD mice. Exp Diabetes Res 2011, 625813. [epub 2011 Nov 28 2011].
15. Bisgin A., Kargi A., Yalcin A.D., Aydin C., Ekinci D., Savas B., et al. Increased serum sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. BMC Cancer 2012, 12(February (1)):58. [epub ahead of print].
16. Liabeuf S., Barreto D.V., Barreto F.C., Chasseraud M., Brazier M., Choukroun G., et al. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 2010, 25(August (8)):2596-2602. [epub 2010 Feb 26].
17. Yalcin A.D., Bisgin A., Kargi A., Gorczynski R.M. Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment. Med Sci Monit 2012, 18(3):PI11-PI15.
18. Bisgin A., Terzioglu E., Aydin C., Yoldas B., Yazisiz V., Balci N., et al. TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis. BMC Musculoskelet Disord 2010, 11(August):192.
19. Shin J.Y., Shin Y.G., Chung C.H. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006, 29(July (7)):1664-1666.